login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VERTEX PHARMACEUTICALS INC (VRTX) Stock News
USA
- NASDAQ:VRTX -
US92532F1003
-
Common Stock
421.2
USD
+11.73 (+2.86%)
Last: 11/10/2025, 8:00:02 PM
421.41
USD
+0.21 (+0.05%)
After Hours:
11/10/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VRTX Latest News, Press Relases and Analysis
All
Press Releases
13 days ago - By: Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Bullish Technical Setup
2 days ago - By: Vertex Pharmaceuticals Incorporated
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
4 days ago - By: Benzinga
- Mentions:
GSK
JNJ
LLY
NVO
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included
4 days ago - By: Zacks Investment Research
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
6 days ago - By: Zacks Investment Research
- Mentions:
ANIP
NTLA
CRSP
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
7 days ago - By: Zacks Investment Research
- Mentions:
ANIP
NTLA
CRSP
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
7 days ago - By: Zacks Investment Research
Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
7 days ago - By: Zacks Investment Research
- Mentions:
CGEN
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
7 days ago - By: Investor's Business Daily
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book
7 days ago - By: Bloomberg
Vertex Beats Estimates on Strong Sales of Cystic Fibrosis Drugs
7 days ago - By: Vertex Pharmaceuticals Incorporated
Vertex Reports Third Quarter 2025 Financial Results
8 days ago - By: Zacks Investment Research
- Mentions:
BEAM
NTLA
CRSP
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
8 days ago - By: The Motley Fool
- Mentions:
PFE
2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon
8 days ago - By: The Motley Fool
- Mentions:
NFLX
Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years?
11 days ago - By: Zacks Investment Research
- Mentions:
RIGL
ANIP
EXAS
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
11 days ago - By: Benzinga
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
12 days ago - By: Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Stock Moves -1.23%: What You Should Know
13 days ago - By: Zacks Investment Research
- Mentions:
ALNY
ZTS
EXAS
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
13 days ago - By: Zacks Investment Research
Exploring Analyst Estimates for Vertex (VRTX) Q3 Earnings, Beyond Revenue and EPS
14 days ago - By: Vertex Pharmaceuticals Incorporated
Vertex to Participate in the UBS Global Healthcare Conference on November 11
15 days ago - By: Zacks Investment Research
- Mentions:
ANIP
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
17 days ago - By: Zacks Investment Research
- Mentions:
MA
NFLX
C
ADI
...
Top Stock Reports for Mastercard, Netflix & Citigroup
19 days ago - By: Vertex Pharmaceuticals Incorporated
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
Please enable JavaScript to continue using this application.